Safety and Clinical Management Safety trials of GLP-1 RAs, including liraglutide, tirzepatide, and semaglutide (oral or subcutaneous), indicate that the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite
This effect could lead to or exacerbate a condition called gastroparesis, which can cause symptoms such as abdominal pain and vomiting (2)
Glutathione plays a crucial role in a detoxification system that is fundamental in plants, mammals, and fungi.[3] Aside from its detoxification role it is important for a variety of essential cellular reactions
Furthermore, (-)-Vestitol has been identified as an -glucosidase inhibitor and can bind to the PPAR- receptor, suggesting potential therapeutic effects for diabetes mellitus [39, 40]
R., Martins, O